In heart failure with reduced EF, which drug class is preferable in every patient as initial mortality-reducing therapy?

In heart failure with reduced EF, which drug class is preferable in every patient as initial mortality-reducing therapy?

• A. Beta-Blockers
• B. ACE Inhibitors
• C. Spironolactone
• D. ARBs

Answer: (B)

Blocking the renin-angiotensin system with ACE inhibitors is the mainstay for reducing death in people with heart failure and reduced ejection fraction because it directly counteracts the harmful neurohormonal activation that drives heart remodeling and progression. By preventing the formation of angiotensin II, these drugs lower afterload, reduce aldosterone-mediated salt and water retention, lessen sympathetic activation, and improve cardiac remodeling over time. This combination translates into clear survival benefits across a broad range of patients with reduced EF, making ACE inhibitors the preferred initial mortality-reducing therapy whenever there are no contraindications (such as significant hyperkalemia, advanced kidney disease, or bilateral renal artery stenosis). While beta-blockers, spironolactone, and ARBs also have mortality benefits, they are employed in more specific situations or after stabilization, whereas ACE inhibitors are applicable to virtually all patients with HFrEF as the starting cornerstone.

Blocking the renin-angiotensin system with ACE inhibitors is the mainstay for reducing death in people with heart failure and reduced ejection fraction because it directly counteracts the harmful neurohormonal activation that drives heart remodeling and progression. By preventing the formation of angiotensin II, these drugs lower afterload, reduce aldosterone-mediated salt and water retention, lessen sympathetic activation, and improve cardiac remodeling over time. This combination translates into clear survival benefits across a broad range of patients with reduced EF, making ACE inhibitors the preferred initial mortality-reducing therapy whenever there are no contraindications (such as significant hyperkalemia, advanced kidney disease, or bilateral renal artery stenosis). While beta-blockers, spironolactone, and ARBs also have mortality benefits, they are employed in more specific situations or after stabilization, whereas ACE inhibitors are applicable to virtually all patients with HFrEF as the starting cornerstone.